Academic Head of the HTS and Biological Assays Unit

The Department of Cell Research and Immunology
The George S. Wise Faculty of Life Sciences

 Dr. Miguel Weil is an associate professor in the Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University. Born in Argentina, Weil immigrated to Israel in 1983. He gained his BSc, MSc and PhD at the Hebrew University of Jerusalem, specializing in developmental neurobiology. He joined the Tel Aviv University in 1998 after completing his postdoctoral studies as a European Molecular Biology Organization (EMBO) fellow at University College London.

Weil served as Head of the Smolarz Family Graduate School of Life Sciences for 6 years and is the founder and Director of the Cell Screening Facility for Personalized Medicine (CSFPM). The CSFPM was established in 2010 as the first fully automated drug-screening facility using image based high content analysis technology in Israel for the purpose of finding potential drug therapies for rare diseases.

Weil’s research group have been involved in developing several human cell based models to find therapeutic solutions for rare diseases. Standard approaches towards drug development are inapplicable for rare diseases, as multi-phase clinical trials cannot be performed to evaluate efficacy due to the low number of patients available. Since a systematic methodology to evaluate the therapeutic efficacy of compounds for rare diseases is lacking, the emergence of image based high content screening/analysis (HCS/HCA) may help to solve this problem using a personalized patient strategy. Weil became an expert in modeling human diseases for personalized medicine using stem cells isolated from biopsies samples of patients suffering from these incurable diseases. Recently the Weil’s group developed a novel approach using image based high content analysis (HCA) to identify disease phenotypes in cells from patients with neurodegenerative and rare diseases.

Weil has greatly contributed to strengthen and to develop active relationships between Tel Aviv University and Latin America and Spain communities. Weil is the recipient of numerous scientific awards and grants, most recently in the areas of neurodegenerative and rare diseases like Amyotrophic Lateral Sclerosis (ALS), Familial Dysautonomia (FD), Duchenne Muscular Dystrophy (DMD) and Adult Polyglucosan Body Disease (APBD).